UNSPSC 51334412: Pinoxepin

This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3YKO9X8N8. European Medicines Agency schedules Pinoxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09856MIG. Pinoxepin generally arises in the molecular formula C23H27CLN2O2.

UNSPSC 51334412 Pinoxepin is a Commodity code under which state and local procurement offices solicit pharmaceutical products, though the code's nominal scope diverges sharply from recent activity. The three most recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer pharmacy program development, and generic multi-source pharmaceutical contracting — none specifically targeting pinoxepin. State and local issuing bodies pursuing pharmaceutical-related work under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The work spans acquisition of pharmaceutical products for community health initiatives, exploratory market intelligence on pharmacy benefit restructuring, and bulk generic drug distribution through authorized wholesalers.

Recent opportunities show geographic spread across Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the due date appears to predate the posting date in the source and should be verified). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs with no binding response deadline attached. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, serving participating states including Oregon. The code shows minimal recent activity specifically aligned to pinoxepin; current activity focuses instead on broader pharmaceutical procurement, pharmacy benefit management reform, and naloxone distribution.